Delårsrapport 1 januari – 30 juni 2017

Pressmeddelandet finns endast på engelska enligt nedan.

 

AroCell AB (publ)
Reporting period 1 April – 30 June 2017

  • Net sales were 237 (0) KSEK
  • Losses after financial items were – 3,606 (- 1,962) KSEK
  • Earnings per share were – 0.27 (- 0.17) SEK
  • Cash flow from operating activities was – 3,163 (- 1,229) KSEK
  • Cash flow from investing activities was – 318 (- 1,800) KSEK

Interim report, 1 January – 30 June 2017

  • Net sales were 293 (0) KSEK
  • Losses after financial items were – 7,831 (- 4,804) KSEK
  • Earnings per share were – 0.27 (- 0.17) SEK

Revenues and expenses April – June 2017 (2016) KSEK

Sales for the period were 237 (0). Expenses were 3,771 (1,962). Taking into account capitalization of R&D, total expenses for the same period in 2016 amounted to 3,762. As the product has been fully developed and CE-marked, R&D expenses are no longer capitalized. According to plan marketing and sales expenses have increased which reflects our ambition to get TK 210 ELISA test to the market. Total cash flow for the period was -3,531 (-3,029). Cash at the end of the period was 24,423.

Revenues and expenses January – June 2017 (2016) KSEK

Sales for the period were 293 (0). Expenses were 8,052 (4,804). Taking into account capitalization of R&D, total expenses for the same period in 2016 amounted to 9,824. As the product has been fully developed and CE-marked, R&D expenses are no longer capitalized. According to plan marketing and sales expenses have increased which reflects our ambition to get TK 210 ELISA test to the market. Total cash flow for the period was -8,429 (-7,521). Cash at the end of the period was 24,423.

AroCell is obliged to make public this information pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through Jan Stålemark, at 08:15 CET on 24 August 2017.

About AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the rate of cell turnover. A tumor has high cell turnover (rate of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategies. The test may also be used for monitoring disease relapse. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please see www.arocell.com. Redeye AB is AroCell:s Certified Adviser. For the full Q2 Interim Report, please refer to the enclosed pdf file Interim report, Q2 2017